<DOC>
	<DOCNO>NCT00994175</DOCNO>
	<brief_summary>Background : - Individuals severe asthma easily control current treatment need new treatment prevent potentially life-threatening asthma attack . Experiments mice find medication call pioglitazone hydrochloride ( Actos ) , use treat patient diabetes , may effective treat severe asthma . Researchers interested determine whether Actos effective improving quality life subject severe asthma continue symptom despite maximum standard medical therapy . Objectives : - To assess effectiveness pioglitazone hydrochloride treatment patient severe asthma control standard treatment . Eligibility : - Individuals 18 75 year age diagnose treat severe asthma least 1 year . Design : - Potential participant screen visit determine eligibility study . The visit involve breathe test , chest x ray , heart lung monitoring , blood test . - Eligible participant full medical history answer series questionnaires quality life asthma . - Phase 1 : Patients record lung function asthma symptom morning even 4 week . At end period , patient evaluate breathing , allergy , blood test , well questionnaire . Patients also provide sputum sample . - Phase 2 : Patients receive regular dos either pioglitazone hydrochloride placebo 16 week . Patients return National Institutes Health every 4 week test . - Phase 3 : Wash-out period without study drug 4 week , similar Phase 1 . - Phase 4 : Patients receive regular dos either pioglitazone hydrochloride placebo 16 week . Patients receive placebo give study drug , vice versa . Patients return National Institutes Health every 4 week test . - Phase 5 : Medications stop , patient return National Institutes Health 4 week later final test .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled , Double-Blind Pilot Study Pioglitazone Hydrochloride Severe , Refractory Asthma</brief_title>
	<detailed_description>New therapy need patient asthma sub-optimally controlled standard measure . Pioglitazone hydrochloride ( Actos ) highly selective potent agonist peroxisome proliferator-activated receptor-Gamma ( PPAR Gamma ) . Studies murine model allergic asthma show PPAR Gamma agonists down-regulate allergen-mediated airway inflammation airway hyperresponsiveness . This protocol randomize , placebo-controlled , doubleblind , crossover ( phase II ) pilot study efficacy pioglitazone treatment patient severe , refractory asthma . The primary end-point study quality life determine Asthma Quality Life Questionnaire ( AQLQ ) score . Secondary end-points include index airway inflammation , airflow obstruction , airway hyperreactivity , asthma symptom .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects 18 75 year age , male female , diagnosis severe , refractory asthma , define American Thoracic Society , least one year . Subjects must history reversible airflow obstruction define positive methacholine bronchoprovocation challenge positive response inhale bronchodilator point course disease great 20 % variability Forced Expiratory Volume 1 second ( FEV1 ) peak expiratory flow ( PEF ) document serial measurement lung function time . Left ventricular ejection fraction great equal 50 % echocardiogram For woman childbearing potential , negative pregnancy test prior study willingness adhere reliable birth control method study . Subjects must ability provide informed consent EXCLUSION CRITERIA : A known history hypersensitivity pioglitazone . Asthma exacerbation require treatment additional oral corticosteroid previous 6 week , lifethreatening asthma attack require cardiopulmonary support previous 6 month . Cigarette smoke within previous 12 month prior history &gt; 20 cumulative packyears . Investigational therapy indication within I month prior screen visit . History lung disease asthma ( ie. , COPD , sarcoidosis ) . History diabetes mellitus require treatment medication , insulin secrete tumor , symptomatic hypoglycemia . HIV/AIDS History congestive heart failure current symptom consistent NYHA classification II , Ill IV . Preexisting edema ( 2+ great ) . Hemoglobin &lt; 11 gm/dl male &lt; 10 gm/dl female . Active liver disease abnormal liver function test &gt; 2 time upper limit normal . History bladder colon cancer . History cancer remission . Active breast feeding . Use following medication , interact pioglitazone : Gemfibrizol ( Lopid ) Atazanivir ( Reyataz ) Ritonavir ( Norvir ) Rifampin ( Rifadpin ) Carbamzepine ( Tegretol ) Phenobarbital ( Luminal ) Phenytoin ( Dilantin ) Rifapentine ( Priftin ) Secobarbital ( Seconal ) Amiodarone ( Cordarone , Pacerone ) Palitaxel ( Taxol ) Replaglinide ( Prandine ) Ketoconazole ( Nizoral ) Atorvastatin ( Lipitor ) Fosphenytoin ( Cerebyx ) Itraconazole ( Sporanox ) Trimethoprim ( Bactrim ) Thioridazine Certain overthecounter herb supplement . These review investigator possible interaction study medication A determination whether supplement safe use pioglitazone make casebycase basis . Any condition , investigator opinion , place patient undue risk complication pioglitazone therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 23, 2017</verification_date>
	<keyword>Pioglitazone</keyword>
	<keyword>Severe , Refractory Asthma</keyword>
	<keyword>Peroxisome Proliferator-Activated Receptor Gamma</keyword>
	<keyword>Airflow Obstruction</keyword>
	<keyword>Airway Inflammation</keyword>
	<keyword>Asthma</keyword>
</DOC>